US-based Emergent’s anthrax vaccine gets FDA clearance
HQ Team July 21, 2023: Emergent BioSolutions Inc., a US developer of vaccines for infectious diseases, announced its anthrax vaccine has been approved.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team July 21, 2023: Emergent BioSolutions Inc., a US developer of vaccines for infectious diseases, announced its anthrax vaccine has been approved.
HQ Team July 24, 2023: US-based Verrica Pharmaceuticals, a dermatology therapeutics company, has got FDA approval for a drug to treat a contagious.
HQ Team July 18, 2023: Eli Lilly’s Alzheimer’s experimental drug, donanedab, slowed down cognitive and functional decline in people with early symptoms of.
HQ Team July 14, 2023: The FDA has approved the first daily oral contraceptive pill, Opill, without prescription to be sold in the.
HQ Team July 12, 2023: Xylazine hydrochloride, a sedative used in animals to provide relief from pain, is increasingly being found in the.
HQ Team July 11, 2023: The FDA has told e-cigarette maker Fontem US, LLC, not to market or distribute its product myblu menthol.
HQ Team July 7, 2023: The USFDA has granted a standard approval for Eisai and Biogen’s Alzheimer injection, Leqembi —the first treatment to secure the.
HQ Team June 22, 2023: Two United States companies have announced that the FDA and the Department of Agriculture have approved their plan.
HQ Team June 21, 2023: British pharmaceutical company, GSK Plc’s vaccine against the respiratory syncytial virus has shown positive data on its efficacy.
HQ Team June 21, 2023: The USFDA has approved Pfizer Inc’s oral Talzenna drug in combination with Xtandi to treat advanced prostate cancer.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com